Yonsei university health system, Severance Hospital

Seoul 3722

7 studies enrolling now · 53 studies all time

What they study most

Advanced Breast Cancer, Advanced Cancer, Advanced Cholangiocarcinoma, Advanced Malignant Solid Tumors, Advanced Solid Tumor, Advanced Solid Tumors, Advanced Solid Tumors or Lymphomas, Advanced Solid Tumours, Anal Cancer, Anal Neoplasm, Anatomic Stage IV Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8

Studies at this site

• A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer — Recruiting now
• Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement — Recruiting now
• Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers — Recruiting now
• A Study of Lorigerlimab in Participants With Advanced Solid Tumors — Recruiting now
• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements — Recruiting now
• Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) — Recruiting now
• GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors — Recruiting now
• Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread — Recruiting now
• A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC — Recruiting now
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) — Recruiting now
• Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer — Running, not enrolling
• Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Running, not enrolling
• A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) — Running, not enrolling
• Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival — Completed
• Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma — Running, not enrolling
• A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma — Running, not enrolling
• Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) — Running, not enrolling
• RegoNivo vs Standard of Care Chemotherapy in AGOC — Completed
• A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis — Running, not enrolling
• A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) — Completed
• Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery — Running, not enrolling
• A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors — Stopped early
• A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers — Stopped early
• HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer — Running, not enrolling
• Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery — Completed
• Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements — Stopped early
• IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer — Completed
• Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease — Stopped early
• Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy — Completed
• Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer — Status unconfirmed
• CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells — Status unconfirmed
• A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) — Completed
• Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery — Running, not enrolling
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease — Completed
• Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer — Completed
• Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide — Status unconfirmed
• A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread — Stopped early
• A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors — Completed
• A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer — Status unconfirmed
• Registry Study for Talimogene Laherparepvec — Completed
• Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) — Completed
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis — Completed
• Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo — Completed
• A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas — Completed
• A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors — Completed
• Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee — Completed
• A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370) — Completed
• Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies — Completed
• Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer — Completed